Zexipag 200mcg Tablet contains Selexipag, a selective prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH). Selexipag works by targeting the prostacyclin pathway, leading to vasodilation of pulmonary arteries and inhibition of vascular smooth muscle cell proliferation, thereby reducing pulmonary vascular resistance and improving exercise capacity. Zexipag is administered orally and is typically used as part of a comprehensive treatment regimen for PAH to delay disease progression and improve patient outcomes. The recommended dosage should be individualized based on patient tolerability and clinical response, with careful titration to minimize adverse effects such as headache, jaw pain, nausea, and flushing. Regular monitoring of liver function and hemodynamic parameters is advised during therapy. Zexipag is contraindicated in patients with hypersensitivity to Selexipag or any of its excipients. Caution is warranted in patients with severe hepatic impairment and those receiving concomitant medications that may interact via cytochrome P450 pathways. As with all PAH therapies, adherence to prescribed dosing and ongoing clinical evaluation are essential to optimize therapeutic benefits and manage potential side effects. Zexipag 200mcg Tablet represents an important pharmacological option in the management of PAH, improving quality of life and functional capacity.